Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18790657 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18788938 | CAPSID VARIANTS AND METHODS OF USING THE SAME | July 2024 | April 2025 | Allow | 8 | 1 | 0 | No | No |
| 18537448 | PREFUSION PIV F IMMUNOGENS AND THEIR USE | December 2023 | May 2025 | Allow | 17 | 1 | 1 | No | No |
| 18526015 | CORONAVIRUS VACCINE FORMULATIONS | December 2023 | June 2025 | Allow | 18 | 1 | 1 | No | No |
| 18521590 | MATERIALS AND METHODS FOR TREATING CANCER | November 2023 | May 2025 | Allow | 18 | 1 | 1 | No | No |
| 18517808 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | September 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18471955 | BIVALENT DENGUE/HEPATITUS B VACCINES | September 2023 | April 2025 | Allow | 18 | 2 | 1 | No | No |
| 18463609 | IMMUNITY-INDUCING AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | September 2023 | October 2024 | Allow | 13 | 0 | 1 | No | No |
| 18453078 | SIMIAN ADENOVIRAL VECTORS WITH TWO EXPRESSION CASSETTES | August 2023 | August 2024 | Allow | 12 | 0 | 1 | No | No |
| 18200421 | EXPRESSION SYSTEMS | May 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18314490 | BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV | May 2023 | May 2025 | Allow | 24 | 1 | 1 | No | No |
| 18311056 | VACCINES AGAINST CORONAVIRUS AND METHODS OF USE | May 2023 | February 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18310066 | Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus | May 2023 | October 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18299676 | VACCINATION IN NEWBORNS AND INFANTS | April 2023 | April 2025 | Allow | 24 | 1 | 1 | No | No |
| 18113776 | NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY | February 2023 | June 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18172741 | Anti-Inflammatory Polypeptides | February 2023 | April 2025 | Allow | 26 | 1 | 0 | No | No |
| 18164988 | HIV-1 ENV FUSION PEPTIDE IMMUNOGENS AND THEIR USE | February 2023 | July 2025 | Allow | 29 | 2 | 1 | No | No |
| 18150430 | AAV CHIMERAS | January 2023 | July 2024 | Allow | 19 | 1 | 1 | No | No |
| 18061831 | CORONAVIRUS VACCINE FORMULATIONS | December 2022 | April 2025 | Allow | 29 | 2 | 1 | No | No |
| 18074220 | INFLUENZA B VIRUS MUTANTS AND USES THEREFOR | December 2022 | April 2025 | Allow | 29 | 1 | 1 | No | No |
| 18059269 | METHODS OF PACKAGING MULTIPLE ADENO-ASSOCIATED VIRUS VECTORS | November 2022 | June 2025 | Allow | 30 | 1 | 0 | No | No |
| 17931215 | METHODS AND COMPOSITIONS FOR STIMULATING IMMUNE RESPONSE | September 2022 | August 2024 | Allow | 23 | 1 | 1 | No | No |
| 17818610 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | August 2022 | May 2025 | Abandon | 33 | 1 | 1 | No | No |
| 17816788 | FORMULATIONS FOR SMALL INTESTINAL DELIVERY OF RSV AND NOROVIRUS ANTIGENS | August 2022 | August 2024 | Allow | 24 | 1 | 1 | No | No |
| 17750896 | TREATMENT OF INSECT BITE HYPERSENSITIVITY | May 2022 | October 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17747713 | IMMUNOGENIC COMPOSITIONS AGAINST INFLUENZA | May 2022 | January 2025 | Allow | 32 | 1 | 1 | No | No |
| 17754877 | Vaccine Product | April 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17544418 | AAV PRODUCTION USING SUSPENSION ADAPTED CELLS | December 2021 | November 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17530103 | TREATMENT OF PRURITUS IN HORSES | November 2021 | July 2024 | Allow | 32 | 1 | 1 | Yes | No |
| 17496250 | ANTIBODIES THAT TARGET HIV GP120 AND METHODS OF USE | October 2021 | March 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17408104 | METHODS OF PREDICTING ANCESTRAL VIRUS SEQUENCES AND USES THEREOF | August 2021 | March 2025 | Allow | 42 | 3 | 1 | No | No |
| 17402973 | USE OF VISTA AGONISTS AND ANTAGONISTS TO SUPPRESS OR ENHANCE HUMORAL IMMUNITY | August 2021 | May 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17374399 | VACCINE AGAINST INFECTIOUS BRONCHITIS | July 2021 | October 2024 | Allow | 39 | 2 | 1 | No | No |
| 17333052 | VACCINE COMPOSITION FOR PREVENTING RABIES, AND PREPARATION METHOD THEREOF | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | No |
| 17306884 | METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY | May 2021 | March 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17227527 | ADENO-ASSOCIATED VIRUS PURIFICATION METHODS | April 2021 | October 2024 | Allow | 43 | 3 | 1 | No | No |
| 17218930 | METHODS AND COMPOSITIONS FOR DETECTING CO-INFECTION WITH SARS-COV-2 AND INFLUENZA A VIRUS AND/OR INFLUENZA B VIRUS | March 2021 | February 2025 | Abandon | 46 | 1 | 2 | No | No |
| 17216660 | METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY | March 2021 | April 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17212051 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS | March 2021 | February 2025 | Abandon | 46 | 4 | 1 | No | No |
| 17249071 | COMPOSITIONS, KITS AND METHODS FOR DETECTION OF VIRAL SEQUENCES | February 2021 | March 2025 | Allow | 49 | 2 | 1 | No | No |
| 17053733 | ADENO-ASSOCIATED VIRUS (AAV) DELIVERY OF ANTI-FAM19A5 ANTIBODIES | November 2020 | September 2024 | Allow | 46 | 3 | 1 | No | No |
| 17051296 | LENTIVIRAL-BASED VECTORS AND RELATED SYSTEMS AND METHODS FOR EUKARYOTIC GENE EDITING | October 2020 | April 2025 | Allow | 53 | 2 | 1 | No | No |
| 17038031 | LENTIVIRAL VECTOR FORMULATIONS | September 2020 | April 2025 | Allow | 55 | 5 | 1 | No | Yes |
| 16978177 | ENGINEERED VEGF VARIANTS FOR RETINAL NEUROPROTECTION, PROMOTION OF AXON GROWTH AND AXON REGENERATION | September 2020 | May 2025 | Allow | 56 | 2 | 1 | Yes | No |
| 16648922 | A GENE THERAPY STRATEGY TO RESTORE ELECTRICAL AND CARDIAC FUNCTION, AND CARDIAC STRUCTURE, IN ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | March 2020 | December 2023 | Allow | 45 | 2 | 1 | No | No |
| 16617805 | A METHOD TO CREATE PERSONALIZED CANCER VACCINES | November 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16614441 | RECOMBINANT ONCOLYTIC VIRUS | November 2019 | February 2025 | Allow | 60 | 5 | 1 | No | No |
| 16604818 | METHODS OF CD40 AND TOLL LIKE RECEPTOR IMMUNE ACTIVATION | October 2019 | August 2024 | Allow | 58 | 4 | 1 | No | No |
| 16481010 | PORCINE CORONAVIRUS VACCINES | July 2019 | June 2024 | Allow | 58 | 4 | 1 | Yes | No |
| 16480939 | B-CELL ENGINEERING | July 2019 | April 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16360278 | PARTICULATE VACCINE FORMULATIONS | March 2019 | May 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 16096673 | RELATIVE POTENCY ASSAY FOR VIRAL VECTOR ENCODING ISOMEROHYDROLASES | October 2018 | March 2025 | Allow | 60 | 3 | 1 | No | Yes |
| 16145848 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | September 2018 | November 2019 | Allow | 13 | 1 | 1 | Yes | No |
| 15964198 | ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES | April 2018 | September 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15964211 | ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES | April 2018 | September 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15863076 | PATTERNED DOSING OF IMMUNOSUPPRESSANTS COUPLED TO SYNTHETIC NANOCARRIERS | January 2018 | December 2024 | Abandon | 60 | 7 | 1 | No | No |
| 15782980 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | October 2017 | August 2019 | Allow | 22 | 1 | 1 | Yes | No |
| 15728460 | INFLAMMASOME ACTIVATORS AND METHODS OF USE TO TREAT TUMORS | October 2017 | May 2020 | Allow | 31 | 2 | 1 | Yes | No |
| 15633906 | METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | June 2017 | April 2019 | Allow | 22 | 1 | 2 | Yes | No |
| 15584674 | A METHOD OF DETECTING AND/OR IDENTIFYING ADENO-ASSOCIATED VIRUS (AAV) SEQUENCES AND ISOLATING NOVEL SEQUENCES IDENTIFIED THEREBY | May 2017 | September 2019 | Allow | 29 | 2 | 2 | Yes | Yes |
| 15232736 | CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR | August 2016 | February 2020 | Allow | 42 | 2 | 2 | Yes | Yes |
| 15172947 | Vaccine and Therapeutic Delivery System | June 2016 | September 2017 | Allow | 15 | 1 | 1 | Yes | No |
| 15035793 | HIV-1 ENV DNA Vaccine Plus Protein Boost Delivered by EP Expands B- and T-Cell Response and Neutralizing | May 2016 | July 2020 | Abandon | 50 | 13 | 1 | No | No |
| 14604215 | VACCINE AND THERAPEUTIC DELIVERY SYSTEM | January 2015 | November 2017 | Allow | 33 | 2 | 1 | Yes | No |
| 14402495 | Antigens and Vaccines Directed Against Human Enteroviruses | November 2014 | March 2018 | Allow | 40 | 3 | 1 | Yes | Yes |
| 14391904 | BISMUTH-CONTAINING CONCENTRATION AGENTS FOR MICROORGANISMS | October 2014 | February 2018 | Allow | 40 | 4 | 1 | No | No |
| 14124706 | PURIFICATION OF BIOLOGICAL PRODUCTS BY CONSTRAINED COHYDRATION CHROMATOGRAPHY | April 2014 | September 2016 | Allow | 33 | 2 | 1 | Yes | No |
| 14129613 | MODIFIED FOOT AND MOUTH DISEASE VIRUS (FMDV) VP1 CAPSID PROTEIN | March 2014 | June 2016 | Allow | 29 | 1 | 1 | Yes | No |
| 14209921 | COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS | March 2014 | July 2018 | Allow | 52 | 4 | 0 | No | No |
| 14207135 | HEPATITIS B VIRUS VACCINES | March 2014 | January 2016 | Allow | 22 | 1 | 1 | No | No |
| 14112388 | SAPOLEGINA PROTEIN IN FOR USE AS A MEDICAMENT | October 2013 | May 2015 | Allow | 19 | 2 | 0 | Yes | No |
| 14110214 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLUENZA VIRUSES REPLICATION | October 2013 | July 2015 | Allow | 21 | 2 | 1 | No | No |
| 14004308 | ADJUVANT COMPOSITION CONTAINING CITRULLINE | September 2013 | March 2016 | Allow | 30 | 3 | 1 | Yes | No |
| 13977108 | Device and Method for Sampling Bodily Fluid for Medical Analytes in Ultra Low Concentrations | September 2013 | March 2016 | Allow | 33 | 2 | 1 | No | No |
| 13980392 | PVRL4 (Nectin4) is a Receptor for Measles Virus | July 2013 | March 2016 | Allow | 32 | 2 | 0 | Yes | No |
| 13979322 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | July 2013 | March 2020 | Allow | 60 | 6 | 2 | Yes | No |
| 13901392 | ORDERED FLAGELLIN ARRAY AS AN IMMUNOSTIMULANT | May 2013 | November 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13636596 | METHODS OF INCREASING EFFICIENCY OF VECTOR PENETRATION OF TARGET TISSUE | April 2013 | October 2016 | Allow | 48 | 2 | 1 | No | Yes |
| 13823735 | ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE | March 2013 | February 2016 | Allow | 35 | 2 | 1 | Yes | No |
| 13668052 | PLASMINOGEN-ACTIVATING ANTIBODY, USE AND PRODUCING METHOD THEREOF AND AGENT INCLUDING THE SAME | November 2012 | March 2014 | Allow | 16 | 2 | 1 | No | No |
| 13530891 | BINDING MEMBERS FOR HUMAN CYTOMEGALOVIRUS | June 2012 | January 2016 | Allow | 43 | 4 | 0 | Yes | No |
| 13501371 | INFECTIOUS CLONES OF TORQUE TENO VIRUS | June 2012 | July 2014 | Allow | 28 | 1 | 1 | Yes | No |
| 13499697 | METHOD, KIT, PLASMID AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE TO DENGUE VIRUS, ON THE BASIS OF DNA AND CHIMERIC VIRUS VACCINES | June 2012 | May 2019 | Allow | 60 | 7 | 1 | Yes | Yes |
| 13378391 | RECOMBINANT RSV VACCINES | December 2011 | June 2016 | Allow | 54 | 3 | 1 | Yes | No |
| 13319813 | PEPTIDIC ANTIGEN THAT INDUCES ANTIBODY RECOGNIZING THREE-DIMENSIONAL STRUCTURE OF HIV AND METHOD FOR SYNTHESIZING SAME | November 2011 | April 2015 | Allow | 41 | 2 | 1 | Yes | No |
| 12937981 | COMBINATION OF MAL AND CADMI MARKERS FOR HPV INDUCED INVASIVE CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONS | January 2011 | December 2015 | Allow | 60 | 3 | 1 | Yes | No |
| 12699340 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS | February 2010 | September 2015 | Allow | 60 | 4 | 2 | Yes | No |
| 11275842 | CULTURING CIRCULAR SSDNA VIRUSES FOR THE PRODUCTION OF VACCINES | January 2006 | April 2007 | Allow | 14 | 1 | 1 | No | No |
| 10990204 | ESCAPE MUTANTS OF NEWCASTLE DISEASE VIRUS AS MARKER VACCINES | November 2004 | September 2005 | Allow | 10 | 1 | 0 | No | No |
| 10826929 | DNA VACCINE EXPRESSING HA1 OF EQUINE-2 INFLUENZA VIRUS | April 2004 | March 2007 | Allow | 35 | 3 | 0 | No | No |
| 10807194 | GENETICALLY BIOTINYLATED RECOMBINANT ANTIBODY IN IMMUNOFILTRATION ASSAY BY LIGHT ADDRESSABLE POTENTIOMETRIC SENSOR FOR IDENTIFICATION OF VENEZUELAN EQUINE ENCEPHALITIS VIRUS | March 2004 | August 2007 | Allow | 40 | 2 | 0 | No | No |
| 10729421 | IDENTIFICATION OF OLIGONUCLEOTIDES FOR THE CAPTURE, DETECTION AND QUANTITATION OF WEST NILE VIRUS | December 2003 | June 2006 | Allow | 30 | 1 | 1 | No | No |
| 10694247 | ORALLY-ADMINISTERED INTERFERON-TAU COMPOSITIONS AND METHODS | October 2003 | February 2007 | Allow | 40 | 2 | 0 | No | Yes |
| 10682739 | 12832, A NOVEL HUMAN KINASE-LIKE MOLECULE AND USES THEREOF | October 2003 | December 2006 | Allow | 38 | 2 | 0 | No | No |
| 10654737 | METHOD FOR GENERATING INFLUENZA VIRUSES AND VACCINES | September 2003 | October 2005 | Allow | 25 | 1 | 0 | No | No |
| 10608029 | ATTENUATED FLAVIVIRUS STRAINS CONTAINING A MUTATED M-ECTODOMAIN AND THEIR APPLICATIONS | June 2003 | September 2006 | Allow | 39 | 1 | 2 | Yes | No |
| 10459155 | IMMUNIZATION AGAINST FLAVIVIRUS | June 2003 | January 2006 | Allow | 31 | 2 | 0 | No | Yes |
| 10388327 | ALPHAVIRUS RNA REPLICON SYSTEMS | March 2003 | February 2007 | Allow | 47 | 2 | 0 | No | No |
| 10354606 | COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF EPIZOOTIC CATARRHAL ENTERITIS IN FERRETS | January 2003 | January 2006 | Abandon | 35 | 2 | 1 | No | No |
| 10231405 | IN VITRO ACTIVITY ASSAY FOR HUMAN HEPATITIS B VIRUS (HBV) DNA POLYMERASE, AND ITS USE FOR SCREENING FOR INHIBITORS OF HBV DNA POLYMERASE | August 2002 | September 2005 | Allow | 37 | 3 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALVOZA, M FRANCO G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SALVOZA, M FRANCO G works in Art Unit 1671 and has examined 100 patent applications in our dataset. With an allowance rate of 83.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 34 months.
Examiner SALVOZA, M FRANCO G's allowance rate of 83.0% places them in the 50% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SALVOZA, M FRANCO G receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by SALVOZA, M FRANCO G is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +23.2% benefit to allowance rate for applications examined by SALVOZA, M FRANCO G. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 41.0% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 60.9% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 4.8% of allowed cases (in the 78% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.